SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 18:46:56 15/05/2024 BST | ||
| 3.76 EUR | -0.79% |
|
| Current month | -1.04% | ||
| 1 month | +9.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 15/05/24 | 3.76 | -0.79% |
| 14/05/24 | 3.79 | +1.07% |
| 13/05/24 | 3.75 | -0.79% |
| 10/05/24 | 3.78 | -1.56% |
| 09/05/24 | 3.84 | -1.29% |
Delayed Quote Deutsche Boerse AG
Last update May 15, 2024 at 06:46 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VX9H9M |
| ISIN | DE000VX9H9M2 |
| Date issued | 04/04/2022 |
| Strike | 85.52 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.45 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.91 € |
|---|---|
| Lowest since issue | 0.58 € |
| Spread | 0.01 € |
| Spread % | 0.26% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
44.71
USD
Average target price
53.19
USD
Spread / Average Target
+18.98%
- Stock Market
- Certificates
- Certificat
